«I highly respect Novocell technologies and am pleased to collaborate with Novocell and explore the potential of their hES cell to
islet cell advances in combination with our iPS cells as a potential new sources for the generation of cellular models and therapies for diabetes,» said Dr. Yamanaka, Director of Center for iPS Research and Application at Kyoto University.
Not exact matches
Complementing this work are recent
advances at Joslin identifying new
islet growth in patients with long - standing type 1 diabetes, as well as identifying potential
islet growth factors, which occur in situations of insulin resistance, that could be used to stimulate the growth of the patient's own beta
cells.
The company is the first to
advance an encapsulated
islet cell replacement therapy for type 1 diabetes into clinical trials.
The company is the first to
advance an encapsulated
islet cell replacement therapy for type -LSB-...]